Emany Joins Beam Therapeutics as CFO
Portfolio - People | Dec 06, 2024 | EIN
Beam Therapeutics, a biotechnology firm at the forefront of genetic medicine development, has announced the appointment of Sravan K. Emany as Chief Financial Officer effective December 19, 2024. Emany is known for his extensive experience in finance and operations, having previously held significant roles at Ironwood Pharmaceuticals and Integra LifeSciences Holdings. At Beam, he will oversee capital formation and allocation strategies as the company advances its portfolio of genetic therapies. Emany expressed excitement at joining a leader in scientific innovation, emphasizing opportunities to contribute to life-changing therapies across its clinical pipeline. The announcement underscores Beam’s commitment to robust management as it seeks to make precision genetic medicine more accessible. Investors are advised to be mindful of forward-looking statements, which are susceptible to risks such as regulatory hurdles and market competition. With its proprietary base editing technology, Beam is positioned to potentially revolutionize the treatment of genetic diseases.
Sectors
- Biotechnology
- Pharmaceuticals
- Financial Services
Geography
- United States – Beam Therapeutics is based in the United States and Sravan Emany’s previous key roles were in American corporations, emphasizing the U.S. biotechnology and financial markets.
Industry
- Biotechnology – Beam Therapeutics operates within the biotechnology industry, focusing on developing precision genetic medicines through base editing technology.
- Pharmaceuticals – The involvement of Sravan Emany, previously of Ironwood Pharmaceuticals, reflects the cross-sector expertise in pharmaceuticals and biotechnology for financial and operational strategies.
- Financial Services – Sravan K. Emany's background includes extensive experience in mergers and acquisitions investment banking, impacting strategic financial planning at Beam Therapeutics.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Beam Therapeutics Inc. | Company appointing new CFO | Company | A biotechnology firm focused on precision genetic medicines through innovative base editing technology. |
| Sravan K. Emany | Appointed Chief Financial Officer | Person | An experienced finance and operations executive with a history of leadership at Ironwood Pharmaceuticals and Integra LifeSciences. |
| Ironwood Pharmaceuticals, Inc. | Sravan Emany's previous employer | Company | A pharmaceuticals company where Sravan K. Emany previously served as CFO and Chief Operating Officer. |
| Integra LifeSciences Holdings Corporation | Sravan Emany's previous employer | Company | A global healthcare company where Mr. Emany served in strategy and financial roles. |
| Bank of America | Former Employer | Company | Sravan Emany worked in mergers and acquisitions investment banking roles here. |
| BofA Securities | Former Employer | Company | Previously known as Bank of America Merrill Lynch, where Mr. Emany was managing director in the M&A group. |
| Goldman Sachs Group | Former Employer | Company | A financial services firm where Mr. Emany held various financial roles. |
| Morgan Stanley | Former Employer | Company | A financial services firm where Mr. Emany held various financial roles. |